{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T03:22:05Z","timestamp":1791602525523,"version":"4.3.4"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T00:00:00Z","timestamp":1657065600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological and Toxicological Methods"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.vascn.2022.107193","type":"journal-article","created":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T11:43:49Z","timestamp":1656762229000},"page":"107193","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["hERG block potencies for 5 positive control drugs obtained per ICH E14\/S7B Q&As best practices: Impact of recording temperature and drug loss"],"prefix":"10.1016","volume":"117","author":[{"given":"Claudia","family":"Alvarez Baron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Thiebaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Viatchenko-Karpinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amruta","family":"Indapurkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murali K.","family":"Matta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omnia A.","family":"Ismaiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikram","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manni","family":"Mashaee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Vicente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy W.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.vascn.2022.107193_bb0005","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/sj.bjp.0706678","article-title":"Mechanism of hERG K+ channel blockade by the fluoroquinolone antibiotic moxifloxacin","volume":"147","author":"Alexandrou","year":"2006","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.vascn.2022.107193_bb0010","author":"Bioanalytical Method Validation"},{"issue":"1","key":"10.1016\/j.vascn.2022.107193_bb0015","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.vascn.2008.10.004","article-title":"Test article concentrations in the hERG assay: Losses through the perfusion, solubility and stability","volume":"59","author":"Brimecombe","year":"2009","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"2","key":"10.1016\/j.vascn.2022.107193_bb0020","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.pharmthera.2010.08.008","article-title":"An evaluation of hERG current assay performance: Translating preclinical safety studies to clinical QT prolongation","volume":"129","author":"Gintant","year":"2011","journal-title":"Pharmacology & Therapeutics"},{"issue":"3","key":"10.1016\/j.vascn.2022.107193_bb0025","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.yrtph.2013.10.001","article-title":"In vitro safety cardiovascular pharmacology studies: Impact of formulation preparation and analysis","volume":"67","author":"Goineau","year":"2013","journal-title":"Regulatory Toxicology and Pharmacology"},{"issue":"8","key":"10.1016\/j.vascn.2022.107193_bb0030","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.hrthm.2005.04.029","article-title":"Exaggerated block of hERG (KCNH2) and prolongation of action potential duration by erythromycin at temperatures between 37 degrees C and 42 degrees C","volume":"2","author":"Guo","year":"2005","journal-title":"Heart Rhythm"},{"issue":"4\u20135","key":"10.1016\/j.vascn.2022.107193_bb0035","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1159\/000322319","article-title":"The novel mechanism of oxymatrine affecting HERG currents at different temperatures","volume":"26","author":"Hu","year":"2010","journal-title":"Cellular Physiology and Biochemistry"},{"key":"10.1016\/j.vascn.2022.107193_bb0040","author":"ICH E14"},{"key":"10.1016\/j.vascn.2022.107193_bb0045","author":"ICH E14\/S7B IWG"},{"key":"10.1016\/j.vascn.2022.107193_bb0050","author":"ICH S7b"},{"issue":"7","key":"10.1016\/j.vascn.2022.107193_bb0055","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1002\/jat.3074","article-title":"Assessment of temperature-induced hERG channel blockade variation by drugs","volume":"35","author":"Kauthale","year":"2015","journal-title":"Journal of Applied Toxicology"},{"issue":"2","key":"10.1016\/j.vascn.2022.107193_bb0060","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.vascn.2004.06.003","article-title":"Variability in the measurement of hERG potassium channel inhibition: Effects of temperature and stimulus pattern","volume":"50","author":"Kirsch","year":"2004","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"2","key":"10.1016\/j.vascn.2022.107193_bb0065","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.vascn.2010.02.007","article-title":"Investigating dynamic protocol-dependence of hERG potassium channel inhibition at 37 degrees C: Cisapride versus dofetilide","volume":"61","author":"Milnes","year":"2010","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"1","key":"10.1016\/j.vascn.2022.107193_bb0070","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.vascn.2009.04.198","article-title":"Effect of compound plate composition on measurement of hERG current IC(50) using PatchXpress","volume":"60","author":"Mo","year":"2009","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"3","key":"10.1016\/j.vascn.2022.107193_bb0075","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ejpb.2006.06.005","article-title":"Drug adsorption to plastic containers and retention of drugs in cultured cells under in vitro conditions","volume":"64","author":"Palmgren","year":"2006","journal-title":"European Journal of Pharmaceutics and Biopharmaceutics"},{"issue":"4","key":"10.1016\/j.vascn.2022.107193_bb0080","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/bph.14101","article-title":"Can non-clinical repolarization assays predict the results of clinical thorough QT studies? Results from a research consortium","volume":"175","author":"Park","year":"2018","journal-title":"British Journal of Pharmacology"},{"issue":"1","key":"10.1016\/j.vascn.2022.107193_bb0085","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1093\/toxsci\/kfx125","article-title":"An analysis of the relationship between preclinical and clinical QT interval-related data","volume":"159","author":"Pollard","year":"2017","journal-title":"Toxicological Sciences"},{"issue":"3","key":"10.1016\/j.vascn.2022.107193_bb0090","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.vascn.2011.08.004","article-title":"hERG potency estimates based upon dose solution analysis: What have we learned?","volume":"64","author":"Qu","year":"2011","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"1","key":"10.1016\/j.vascn.2022.107193_bb0095","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0008-6363(02)00846-5","article-title":"Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development","volume":"58","author":"Redfern","year":"2003","journal-title":"Cardiovascular Research"},{"issue":"7083","key":"10.1016\/j.vascn.2022.107193_bb0100","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nature04710","article-title":"hERG potassium channels and cardiac arrhythmia","volume":"440","author":"Sanguinetti","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.vascn.2022.107193_bb0105","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.vascn.2017.11.002","article-title":"Comparative analysis of media effects on human induced pluripotent stem cell-derived cardiomyocytes in proarrhythmia risk assessment","volume":"90","author":"Schocken","year":"2018","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2022.107193_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2017.08.006","article-title":"Characterization of loperamide-mediated block of hERG channels at physiological temperature and its proarrhythmia propensity","author":"Sheng","year":"2017","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"3","key":"10.1016\/j.vascn.2022.107193_bb0115","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s40264-013-0016-z","article-title":"Dealing with global safety issues: Was the response to QT-liability of non-cardiac drugs well coordinated?","volume":"36","author":"Stockbridge","year":"2013","journal-title":"Drug Safety"},{"issue":"8","key":"10.1016\/j.vascn.2022.107193_bb0120","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1038\/sj.bjp.0707356","article-title":"State dependent dissociation of HERG channel inhibitors","volume":"151","author":"Stork","year":"2007","journal-title":"British Journal of Pharmacology"},{"issue":"1","key":"10.1016\/j.vascn.2022.107193_bb0125","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1476-5381.2009.00395.x","article-title":"Integrated risk assessment and predictive value to humans of non-clinical repolarization assays","volume":"159","author":"Wallis","year":"2010","journal-title":"British Journal of Pharmacology"},{"issue":"1","key":"10.1016\/j.vascn.2022.107193_bb0130","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1124\/mol.117.111534","article-title":"The temperature dependence of kinetics associated with drug block of hERG channels is compound-specific and an important factor for Proarrhythmic risk prediction","volume":"94","author":"Windley","year":"2018","journal-title":"Molecular Pharmacology"},{"issue":"1","key":"10.1016\/j.vascn.2022.107193_bb0135","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.vascn.2005.04.008","article-title":"Estimation of potency of HERG channel blockers: Impact of voltage protocol and temperature","volume":"52","author":"Yao","year":"2005","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"1","key":"10.1016\/j.vascn.2022.107193_bb0140","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0006-3495(98)77782-3","article-title":"Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature","volume":"74","author":"Zhou","year":"1998","journal-title":"Biophysical Journal"}],"container-title":["Journal of Pharmacological and Toxicological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056871922000405?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056871922000405?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:05:41Z","timestamp":1761005141000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056871922000405"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":28,"alternative-id":["S1056871922000405"],"URL":"https:\/\/doi.org\/10.1016\/j.vascn.2022.107193","relation":{},"ISSN":["1056-8719"],"issn-type":[{"value":"1056-8719","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"hERG block potencies for 5 positive control drugs obtained per ICH E14\/S7B Q&As best practices: Impact of recording temperature and drug loss","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological and Toxicological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vascn.2022.107193","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107193"}}